高级检索
当前位置: 首页 > 详情页

Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ 卓越:梯队期刊 ◇ ESCI

机构: [1]The Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China. [2]Department of Gynecologic, Yunnan Cancer Hospital, Kunming, China. [3]Department of Gynecologic Oncology, Shandong Cancer Hospital, Jinan, China. [4]Department of Gynecologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. [5]Department of Gynecologic Oncology, Hunan Cancer Hospital, Changsha, China. [6]Department of Tumor Radiotherapy and Chemotherapy, West China Second University Hospital of Sichuan University, Chengdu, China. [7]Department of Gynecologic, Guangxi Cancer Institute, Nanning, China. [8]Department of Gynecologic Oncology, Liaoning Cancer Hospital, Shenyang, China. [9]Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China. [10]The Gynecologic Oncology Center, Peking Union Medical College Hospital, Beijing, China. [11]Department of Gynecologic, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
出处:

摘要:
[This corrects the article DOI: 10.1016/j.jncc.2024.04.004.].© 2024 Chinese National Cancer Center. Published by Elsevier B.V.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2024]版:
Q1 ONCOLOGY
最新[2024]版:
Q1 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]The Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59502 今日访问量:0 总访问量:4869 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号